Navigation Links
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
Date:11/26/2008

ibuted to this negative outcome, not only to build upon this insight for our Parkinson's program, but also to help assure continued successful development of our product candidates for other diseases."

About Phase 2 Trial of CERE-120

Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in November 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for 12 months for safety and efficacy.

About CERE-120

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair

damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion. Genzyme Corporation has licensed the ex-North American rights for the development and commercialization of CERE-120 from Ceregene, an agreement that was announced
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Ceregene Announces Two Key Additions to Leadership Team
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... a novel class of intracellular protein biologics, today ... of naturally occurring human supercharged proteins called Intraphilins. ... human proteins enable biologic drugs to penetrate and ... of proteins is the foundation of Permeon Biologics, ...
... form protein clumps in the body, then alarm bells ... associated with Alzheimer,s disease and type 2 diabetes, formerly ... proteins form clumps, then they might be able to ... Keller and his colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and ...
... 2011 Gen-Probe Incorporated (NASDAQ: GPRO ) today ... total revenues of $135.9 million and non-GAAP earnings per share ... of APTIMA women,s health products in the second quarter of ... decline compared to strong sales a year ago," said Carl ...
Cached Biology Technology:Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 2Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 3In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... because these animals are sensitive to changes in their ... mine" to give researchers early warnings about pollution or ... State University shows that data from the largest amphibian ... if uncorrected, could result in overestimates of frog populations. ...
... August 2nd, 2010 - Using little more than PVC rings, ... feel for soil water retention and field capacity, concepts that ... The demonstration, developed by Adam Howard, Drs. Josh Heitman ... to illustrate concepts that can be difficult for students to ...
... culturing adult human stem cells on a new type of ... about how the cells would differentiate, or what type of ... Aug. 1 edition of Nature Methods . Differentiation ... of cells. Understanding it is key to developing future stem ...
Cached Biology News:'Ribbit Radio' shows frog population estimates are likely flawed 2Students get a feel for soil-water relationships 2New insights into how stem cells determine what tissue to become 2
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
... transfer is fast emerging as a powerful ... confirmation. Until now, only amino groups have ... transfer reagents such as our Sulfo-SBED. Sulfhydryl-reactive ... are exciting additions to the protein interaction ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
Biology Products: